Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression.

The Journal of antimicrobial chemotherapy - 1 Jun 2008

Pulido Federico, Delgado Rafael, Pérez-Valero Ignacio, González-García Juan, Miralles Pilar, Arranz Alberto, Hernando Asunción, Arribas José R

Abstract excerpt

OBJECTIVES: Data are scarce on the long-term efficacy of lopinavir/ritonavir monotherapy for the maintenance of HIV suppression. Four years of results of patients randomized to monotherapy in the Only Kaletra (OK) pilot clinical trial are presented. PATIENTS AND METHODS: Twenty-one HIV-infected patients with suppressed HIV replication (<50 copies/mL) for at least 6 months and without previous failure while...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to HIV

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Protease Inhibitors

Share to Longitudinal Studies

Share to Lopinavir

Share to Pyrimidinones

Share to Ritonavir

Share to Viral Load

Source

Identifiers

PMID: 18343802
DOI: 10.1093/jac/dkn103

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression.PMID 18343802Read ↗

Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families.Semantic proximity Read ↗

Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice.Semantic proximity Read ↗

Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.Semantic proximity Read ↗

Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice.Semantic proximity Read ↗

Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations.Semantic proximity Read ↗

[Lopinavir/ritonavir in HIV-infected patient with long-term virological failure: immunovirological response and tolerance in 121 patients of the ANRS CO8 Aproco-Copilote cohort].Semantic proximity Read ↗

Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study).Semantic proximity Read ↗

Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen.Semantic proximity Read ↗

A stable CC-chemokine receptor (CCR)-5 tropic virus is correlated with the persistence of HIV RNA at less than 2.5 copies in successfully treated naïve subjects.Semantic proximity Read ↗

Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics.Semantic proximity Read ↗

Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients.Semantic proximity Read ↗

3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.